NO20064794L - Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon - Google Patents

Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon

Info

Publication number
NO20064794L
NO20064794L NO20064794A NO20064794A NO20064794L NO 20064794 L NO20064794 L NO 20064794L NO 20064794 A NO20064794 A NO 20064794A NO 20064794 A NO20064794 A NO 20064794A NO 20064794 L NO20064794 L NO 20064794L
Authority
NO
Norway
Prior art keywords
cancer
antibodies
methods
cancer cell
cell proliferation
Prior art date
Application number
NO20064794A
Other languages
English (en)
Inventor
Vanitha Ramakrishnan
Vinay Bhaskar
Sun Ho
Richard Murray
Debbie Law
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Publication of NO20064794L publication Critical patent/NO20064794L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

SAMMENDRAG Foreliggende oppfinnelse tilveiebringer fremgangsmåter for direkte dreping av kreftceller ved anvendelse av anti-(5(l-antistoffer. Generelt omfatter fremgangsmåten å kontakte en kreftcelle som uttrykker a5pl på dens overflate med et anti-(5(l-antistoff, og derved indusere død av kreftcellen. Fremgangsmåtene ifølge oppfinnelsen kan anvendes ved et tidlig stadium av kreftutvikling i en pasient for å forhindre etablering av tumor. I tillegg kan fremgangsmåtene anvendes for å behandle tidligere dannede tumorer spesielt ved kreft som ikke har vist seg mottagelig for anti-angiogenese behandling. Fremgangsmåtene kan anvendes som en kombinasjonsterapi av anti-(5(l-antistoffer sammen med kjemoterapeutiske midler mot kreft eller andre molekylærbaserte terapeutiske midler mot kreft.
NO20064794A 2004-03-24 2006-10-23 Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon NO20064794L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55642204P 2004-03-24 2004-03-24
US55642104P 2004-03-24 2004-03-24
US62504904P 2004-11-03 2004-11-03
US65109805P 2005-02-07 2005-02-07
US65751405P 2005-02-28 2005-02-28
PCT/US2005/009939 WO2005092073A2 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Publications (1)

Publication Number Publication Date
NO20064794L true NO20064794L (no) 2006-10-23

Family

ID=35056776

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064794A NO20064794L (no) 2004-03-24 2006-10-23 Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon

Country Status (15)

Country Link
US (2) US7662384B2 (no)
EP (1) EP1755659B1 (no)
JP (1) JP4857259B2 (no)
KR (1) KR20070009637A (no)
AT (1) ATE531388T1 (no)
AU (1) AU2005226736B2 (no)
BR (1) BRPI0509177A (no)
CA (1) CA2560508A1 (no)
DK (1) DK1755659T3 (no)
ES (1) ES2376556T3 (no)
HK (1) HK1101348A1 (no)
IL (1) IL178042A (no)
NO (1) NO20064794L (no)
NZ (1) NZ549893A (no)
WO (1) WO2005092073A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140057635A (ko) 2006-03-15 2014-05-13 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
WO2008060645A2 (en) * 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
KR20090027218A (ko) * 2006-05-24 2009-03-16 바이엘 쉐링 파마 악티엔게젤샤프트 면역원성이 감소된, 고친화도 인간 및 인간화된 항-α5β1 인테그린 작용 블로킹 항체
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
BRPI0813630A2 (pt) * 2007-07-27 2019-09-24 Facet Biotech Corp combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)
AR066170A1 (es) * 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
CA2714071A1 (en) * 2008-02-05 2009-08-13 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
WO2010111254A1 (en) * 2009-03-25 2010-09-30 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
JP6431372B2 (ja) 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド 抗体製剤および方法
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
NO2760138T3 (no) 2012-10-01 2018-08-04
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) * 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3854306B2 (ja) * 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
NZ249677A (en) * 1992-02-19 1996-08-27 Schering Corp Monoclonal antibodies and compositions useful for treating il-4 diseases and intermediates for making such antibodies
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0669988B2 (en) 1992-10-29 2009-07-08 The Australian National University Angiogenesis inhibitory antibodies
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0704920B1 (en) * 1994-09-21 2000-04-19 Matsushita Electric Industrial Co., Ltd. Solid-state lithium secondary battery
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
CA2249733A1 (en) 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
CA2250291A1 (en) 1997-01-29 1998-07-30 Toray Industries Inc. Chimeric proteins, their heterodimer complexes, and platelet substitutes
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
EP1075543A2 (en) 1998-04-27 2001-02-14 Sidney Kimmel Cancer Center Reduced complexity nucleic acid targets and methods of using same
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
PT1075277E (pt) 1998-05-08 2009-05-08 Univ California Métodos para detectar e inibir a angiogénese
MXPA02001439A (es) 1999-08-11 2002-08-30 Eos Biotechnology Inc Nuevos metodos para el diagnostico de angiogenesis, composiciones y metodos de exhibicion de moduladores de la angiogenesis.
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
CA2397665A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
AU2002257004A1 (en) 2001-02-14 2002-10-15 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
BR0316670A (pt) * 2002-11-26 2005-10-11 Protein Design Labs Inc Anticorpos quiméricos e humanizados para integrina (alfa)5ß1 que modulam a angiogênese
CA2520121A1 (en) * 2003-04-03 2004-10-21 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
MX369959B (es) * 2003-05-14 2019-11-27 Immunogen Inc Composicion de farmaco conjugado.

Also Published As

Publication number Publication date
WO2005092073A2 (en) 2005-10-06
EP1755659A2 (en) 2007-02-28
NZ549893A (en) 2010-05-28
US7662384B2 (en) 2010-02-16
BRPI0509177A (pt) 2007-09-18
CA2560508A1 (en) 2005-10-06
HK1101348A1 (en) 2007-10-18
AU2005226736A1 (en) 2005-10-06
JP2007530584A (ja) 2007-11-01
IL178042A (en) 2011-05-31
DK1755659T3 (da) 2012-02-27
WO2005092073A3 (en) 2006-08-10
US20100291111A1 (en) 2010-11-18
KR20070009637A (ko) 2007-01-18
ES2376556T3 (es) 2012-03-14
JP4857259B2 (ja) 2012-01-18
ATE531388T1 (de) 2011-11-15
EP1755659B1 (en) 2011-11-02
IL178042A0 (en) 2006-12-31
AU2005226736B2 (en) 2009-11-26
US20050260210A1 (en) 2005-11-24
EP1755659A4 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
NO20064794L (no) Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon
ATE546158T1 (de) Therapeutisches krebsmittel mit polymergebundenem antikörper
CY1119956T1 (el) Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
EA200601433A1 (ru) Способы и композиции для лечения опухолей и метастазирования
DE602005027617D1 (de) Radiotherapiebehandlungsüberwachung unter einsatz von ultraschall
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
NO20070951L (no) Inhibitorer av angiopoientinlignende-4-protein, kombinasjoner og deres anvendelse.
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
WO2004000094A8 (en) Predictive markers in cancer therapy
CY1114006T1 (el) Τοπικα σκευασματα συνενζυμου q10 και μεθοδοι χρησης
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
TW200626900A (en) Wnt proteins and detection and treatment of cancer
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
DK1680141T3 (da) Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
MX2019015194A (es) Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.
DE60038624D1 (de) Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
UA88294C2 (ru) ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application